Summary & Overview
HCPCS G9111: Head and Neck Squamous Cell Cancer Disease Status
HCPCS Level II code G9111 designates an oncology disease-status classification for head and neck cancers confined to the oral cavity, pharynx, and larynx with squamous cell histology, intended for cases that are metastatic, locally recurrent, progressive, or m1 at diagnosis and used within a Medicare-approved demonstration project. Nationally, this code matters because it standardizes reporting for a defined subset of advanced head and neck cancers and supports demonstration-based data collection and program evaluation.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The content provides a national perspective on clinical context and administrative use rather than payer-specific reimbursement rates. Readers will find a concise explanation of the code’s clinical scope and service settings, an outline of typical sites of service where the code applies, and guidance on where to find missing operational details. The publication flags that payer-specific billing rules, associated taxonomies, ICD-10 pairings, and related codes are not included in the provided input and should be consulted from payer policy manuals or Medicare demonstration documentation for implementation.
This summary serves clinicians, coding professionals, and policy analysts seeking a clear description of G9111 and where it fits in oncology reporting and demonstration project workflows.
Billing Code Overview
HCPCS Level II code G9111 describes an oncology disease status assessment for head and neck cancer, limited to cancers of the oral cavity, pharynx, and larynx with squamous cell as the predominant cell type. The code is specified for cases that are m1 at diagnosis, metastatic, locally recurrent, or progressive and is intended for use in a Medicare-approved demonstration project.
-
Service type: Oncology disease status assessment and reporting within the context of a demonstration project
-
Typical site of service: Hospital outpatient departments, cancer centers, or other oncology specialty settings where disease status evaluations for advanced or recurrent head and neck squamous cell carcinomas are performed
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, payer-specific billing rules, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with a history of tobacco and alcohol use presents to a tertiary oncology center with progressive dysphagia, hoarseness, and a palpable neck mass. Imaging and biopsy confirm squamous cell carcinoma of the oropharynx with radiographic evidence of distant metastasis at diagnosis (M1). The patient is enrolled in a Medicare-approved demonstration project to capture disease-status reporting specific to head and neck squamous cell carcinomas of the oral cavity, pharynx, and larynx. The clinical workflow includes initial evaluation by a head and neck surgical oncologist and medical oncologist, staging with PET/CT and contrast-enhanced CT or MRI, tissue confirmation via biopsy, and multidisciplinary tumor board review. Disease status (metastatic, locally recurrent, or progressive) is documented in the medical record and reported using billing code G9111 during outpatient oncology visits or as part of care coordination for clinical trial/demo project billing. Typical sites of service include outpatient oncology clinics, hospital outpatient departments, and specialized head and neck cancer centers. Common documentation includes history and physical, imaging and pathology reports, treatment history (surgery, radiation, systemic therapy), and explicit statement of disease status (e.g., "metastatic at diagnosis"), which supports use of G9111 under the demonstration project rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |